Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study

Autor: Carson K. L. Lo, Calvin K. F. Lo, Adam S. Komorowski, Victor Leung, Nancy Matic, Susan McKenna, Santiago Perez-Patrigeon, Prameet M. Sheth, Christopher F. Lowe, Zain Chagla, Anthony D. Bai

Publikováno v: BMC Research Notes, Vol 17, Iss 1, Pp 1-6 (2024)

Abstract Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus diseas

Externí odkaz: https://doaj.org/article/2aace75244d9486bbb5f42ff68cead0c

Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials

Autor: Anthony D. Bai, Adam S. Komorowski, Carson K. L. Lo, Pranav Tandon, Xena X. Li, Vaibhav Mokashi, Anna Cvetkovic, Aidan Findlater, Laurel Liang, George Tomlinson, Mark Loeb, Dominik Mertz, the McMaster Infectious Diseases Fellow Research Group

Publikováno v: Trials, Vol 22, Iss 1, Pp 1-10 (2021)

Abstract Background Numerous statistical methods can be used to calculate the confidence interval (CI) of risk differences. There is consensus in previous literature that the Wald method should be discouraged. We compared five statistical methods for

Externí odkaz: https://doaj.org/article/c338145950834745b158fc6611a61acc

Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review

Autor: Anthony D. Bai, Adam S. Komorowski, Carson K. L. Lo, Pranav Tandon, Xena X. Li, Vaibhav Mokashi, Anna Cvetkovic, Aidan Findlater, Laurel Liang, George Tomlinson, Mark Loeb, Dominik Mertz, for the McMaster Infectious Diseases Fellow Research Group

Publikováno v: BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-10 (2021)

Abstract Background In non-inferiority trials, there is a concern that intention-to-treat (ITT) analysis, by including participants who did not receive the planned interventions, may bias towards making the treatment and control arms look similar and

Externí odkaz: https://doaj.org/article/b1fb4bcf333d4b40b49065693f3aef18

What Is the Optimal Follow-up Length for Mortality in Staphylococcus aureus Bacteremia? Observations From a Systematic Review of Attributable Mortality.

Autor: Bai, Anthony D^1,2 (AUTHOR) tony.bai@queensu.ca, Lo, Carson K L³ (AUTHOR), Komorowski, Adam S^2,4 (AUTHOR), Suresh, Mallika⁵ (AUTHOR), Guo, Kevin⁶ (AUTHOR), Garg, Akhil⁷ (AUTHOR), Tandon, Pranav⁸ (AUTHOR), Senecal, Julien⁹ (AUTHOR), Corpo, Olivier Del¹⁰ (AUTHOR), Stefanova, Isabella⁵ (AUTHOR), Fogarty, Clare¹¹ (AUTHOR), Butler-Laporte, Guillaume¹² (AUTHOR), McDonald, Emily G¹³ (AUTHOR), Cheng, Matthew P¹⁴ (AUTHOR), Morris, Andrew M¹⁵ (AUTHOR), Loeb, Mark³ (AUTHOR), Lee, Todd C¹³ (AUTHOR)

Publikováno v: Open Forum Infectious Diseases. May2022, Vol. 9 Issue 5, p1-9. 9p.

More Than a Decade Since the Latest CONSORT Non-inferiority Trials Extension: Do Infectious Diseases Trials Do Enough?

Autor: Komorowski, Adam S, Lo, Carson K L, Kapoor, Andrew K, Smieja, Marek, Loeb, Mark, Mertz, Dominik, Bai, Anthony D

Publikováno v: Clinical Infectious Diseases; 2/15/2024, Vol. 78 Issue 2, p324-329, 6p